Colombel discusses long-term LUCENT extension data showing durable clinical, endoscopic, and histologic outcomes with mirikizumab in moderately to severely active UC.
Jean-Frederic Colombel, MD
Advertisement
Jean-Frederic Colombel, MD, is the Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at the Icahn School of Medicine at Mount Sinai.
Articles by Jean-Frederic Colombel, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
OMA 2026 Recap: Pediatrics, Retention, and Lifestyle Changes in Obesity
2
A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease
3
Choosing Among Approved JAK Inhibitors: Baricitinib, Ritlecitinib, and Deuruxolitinib
4
CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports
5